Other languages MedMira Inc.

Equities

MIR

CA58501R1029

Delayed Toronto S.E. Other stock markets 19:05:10 07/05/2024 BST			5-day change	1st Jan Change
0.085 ^CAD	-5.56%		0.00%	-22.73%

04-02	MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
03-27	Samsung Pay to stop working with Russia's Mir payment system from April 3	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MedMira Inc.: MedMira gibt Einstellung eines Vizepräsidenten für Geschäftsentwicklung bekannt	05-01
MedMira Inc.: MedMira Announces the Hire of Vice President of Business Development	05-01
MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	04-02
Samsung Pay to stop working with Russia's Mir payment system from April 3	03-27
MedMira Inc.: MedMira erhält kanadisches Patent für sein einzigartiges quantitatives Diagnosesystem	03-14
MedMira Inc.: MedMira gibt Unternehmens-Update zur klinischen Bewertung von MedMiras Produkten	02-05
MedMira's Fiscal Q1 Loss Widens, Revenue Drops	01-02
MedMira Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-28
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test	12-14
MedMira Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	11-27
Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests	28/09/23
MedMira's Fiscal Q3 Loss Widens, Revenue Falls	30/06/23
MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	28/06/23
MedMira Falls Near 17% As Widens Q2 Net Loss YOY	04/04/23
MedMira Widens Q2 Net Loss YOY	04/04/23
MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	02/04/23
MedMira Inc. Provides an Update on Its Progress to Achieve Regulatory Approval in Canada for Its Reveal TP Antibody Test	14/03/23
MedMira Enters into Partnership with Maternova for USA and Latin America	21/02/23
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis	20/02/23
MedMira Reports Wider Fiscal Q1 Loss, Lower Revenue	03/01/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MedMira Inc.

Equities

MIR

CA58501R1029

Other languages

Filters